ClinicalTrials.gov
ClinicalTrials.gov Menu

Lifestyle Modification and Metformin Use in the Treatment of HIV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00399360
Recruitment Status : Completed
First Posted : November 14, 2006
Results First Posted : September 14, 2012
Last Update Posted : September 14, 2012
Sponsor:
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Steven K. Grinspoon, MD, Massachusetts General Hospital

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Factorial Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: HIV Infections
Metabolic Syndrome X
Interventions: Drug: Metformin
Drug: Placebo
Behavioral: Lifestyle Modification

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
No Lifestyle Modification and Placebo Participants did not participate in lifestyle modification and took a placebo capsule 500mg twice daily x 3 months, which was increased to 850mg twice daily at the 3 month visit for the duration of the study.
Lifestyle Modification and Placebo Participants participated in lifestyle modification sessions 3 times a week for the duration of the study and took a placebo capsule 500mg twice daily for 3 months which was increased to 850mg twice daily at the 3 month visit for the duration of the study.
No Lifestyle Modification and Metformin Participants did not participate in lifestyle modification and took metformin 500mg twice daily for 3 months, this was increased to 850mg twice daily at the 3 month visit for the duration of the study.
Lifestyle Modification and Metformin Participants participated in lifestyle modification sessions 3 times a week for the duration of the study and took metformin 500mg twice daily for 3 months which was increased to 850mg twice daily at the 3 month visit for the duration of the study.

Participant Flow:   Overall Study
    No Lifestyle Modification and Placebo   Lifestyle Modification and Placebo   No Lifestyle Modification and Metformin   Lifestyle Modification and Metformin
STARTED   11   11   13   15 
COMPLETED   9   8   10   9 
NOT COMPLETED   2   3   3   6 
Lost to Follow-up                2                1                2                4 
Adverse Event                0                0                1                0 
Withdrawal by Subject                0                2                0                2 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
No Lifestyle Modification and Placebo Participants did not participate in lifestyle modification and took a placebo capsule 500mg twice daily x 3 months, which was increased to 850mg twice daily at the 3 month visit for the duration of the study.
Lifestyle Modification and Placebo Participants participated in lifestyle modification sessions 3 times a week for the duration of the study and took a placebo capsule 500mg twice daily for 3 months which was increased to 850mg twice daily at the 3 month visit for the duration of the study.
No Lifestyle Modification and Metformin Participants did not participate in lifestyle modification and took metformin 500mg twice daily for 3 months, this was increased to 850mg twice daily at the 3 month visit for the duration of the study.
Lifestyle Modification and Metformin Participants participated in lifestyle modification sessions 3 times a week for the duration of the study and took metformin 500mg twice daily for 3 months which was increased to 850mg twice daily at the 3 month visit for the duration of the study.
Total Total of all reporting groups

Baseline Measures
   No Lifestyle Modification and Placebo   Lifestyle Modification and Placebo   No Lifestyle Modification and Metformin   Lifestyle Modification and Metformin   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 11   11   13   15   50 
Age 
[Units: Participants]
 		         
<=18 years   0   0   0   0   0 
Between 18 and 65 years   11   11   13   15   50 
>=65 years   0   0   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation) 		 47  (6)   49  (8)   45  (9)   47  (8)   47  (7) 
Gender 
[Units: Participants]
 		         
Female   4   3   3   2   12 
Male   7   8   10   13   38 
Race (NIH/OMB) 
[Units: Years]
 		         
American Indian or Alaska Native   0   0   0   0   0 
Asian   0   0   1   0   1 
Native Hawaiian or Other Pacific Islander   0   0   0   0   0 
Black or African American   4   4   3   5   16 
White   7   6   9   10   32 
More than one race   0   0   0   0   0 
Unknown or Not Reported   0   1   0   0   1 
Region of Enrollment 
[Units: Participants]
 		         
United States   11   11   13   15   50 


  Outcome Measures

1.  Primary:   Carotid Intima Media Thickness   [ Time Frame: baseline and 12 months ]
  Show Outcome Measure 1

2.  Primary:   Waist Circumference   [ Time Frame: baseline and 12 months ]
  Show Outcome Measure 2

3.  Primary:   High Density Lipoprotein (HDL)   [ Time Frame: baseline and 12 months ]
  Show Outcome Measure 3

4.  Primary:   Glucose   [ Time Frame: baseline and 12 months ]
  Show Outcome Measure 4

5.  Primary:   Systolic Blood Pressure   [ Time Frame: baseline and 12 months ]
  Show Outcome Measure 5

6.  Primary:   Coronary Artery Calcium Score   [ Time Frame: baseline and 12 months ]
  Show Outcome Measure 6

7.  Secondary:   C-reactive Protein   [ Time Frame: baseline and 12 months ]
  Show Outcome Measure 7

8.  Secondary:   Abdominal Visceral Adiposity   [ Time Frame: baseline and 12 months ]
  Show Outcome Measure 8

9.  Secondary:   Cardiorespiratory Fitness   [ Time Frame: baseline and 12 months ]
  Show Outcome Measure 9

10.  Secondary:   Intramyocellular Lipid   [ Time Frame: baseline and 12 months ]
  Show Outcome Measure 10


  Serious Adverse Events

Time Frame 12 months
Additional Description safety visits occurred at 1, 3, 6, and 9 months during which time ALT, creatinine, lactate level and CBC were checked

Reporting Groups
  Description
No Lifestyle Modification and Placebo Participants did not participate in lifestyle modification and took a placebo capsule 500mg twice daily x 3 months, which was increased to 850mg twice daily at the 3 month visit for the duration of the study.
Lifestyle Modification and Placebo Participants participated in lifestyle modification sessions 3 times a week for the duration of the study and took a placebo capsule 500mg twice daily for 3 months which was increased to 850mg twice daily at the 3 month visit for the duration of the study.
No Lifestyle Modification and Metformin Participants did not participate in lifestyle modification and took metformin 500mg twice daily for 3 months, this was increased to 850mg twice daily at the 3 month visit for the duration of the study.
Lifestyle Modification and Metformin Participants participated in lifestyle modification sessions 3 times a week for the duration of the study and took metformin 500mg twice daily for 3 months which was increased to 850mg twice daily at the 3 month visit for the duration of the study.

Serious Adverse Events
    No Lifestyle Modification and Placebo   Lifestyle Modification and Placebo   No Lifestyle Modification and Metformin   Lifestyle Modification and Metformin
Total, Serious Adverse Events         
# participants affected / at risk   0/11 (0.00%)   0/11 (0.00%)   0/13 (0.00%)   0/15 (0.00%) 




  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The study was relatively small and may have been underpowered to assess effect on secondary endpoints and to assess the effects of lifestyle modification. The sample size may have limited our ability to determine differences in dropout rates.


  More Information